ArticleInfection and drug resistance2025
Successful Treatment of Mucormycosis and Azole-Resistant
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mixed InvasiveRespirology case reports · 2026Article
- Diverse Presentations of Invasive Aspergillus and Mucorales Infections in Immunocompromised Patients: A Case Series.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To report a case of coinfection with mucormycosis and azole-resistant Methods: A 52-year-old man who presented to our hospital with a 1-month history of fever accompanied by productive cough and sputum. He had type 2 diabetes with poor control of glucose level. Chest computed tomography (CT) showed rapidly progressive multiple cavities and consolidation in the lungs. Sputum culture showed azole-resistant Results: Following the initiation of high-dose posaconazole and liposomal amphotericin B, the patient's temperature normalized, and pulmonary exudates significantly improved. Therapeutic drug monitoring (TDM) showed that posaconazole trough concentrations were maintained at 3-4 mg/L without significant hepatic or renal toxicity. The main adverse effects observed were hypokalemia and anorexia. After 102 days of antifungal therapy, the patient underwent successful lobectomy, leading to complete resolution of symptoms. Conclusion: This case demonstrated the good efficacy and safety of high-dose posaconazole combined with liposomal amphotericin B in the treatment of azole-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.